Track Enovis Corporation Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Enovis Corporation Common Stock ENOV Open Enovis Corporation Common Stock in new tab

25.25 USD
EPS
-19.89
P/B
0.98
ROE
-55.35
Beta
1.52
Target Price
43.00 USD
Enovis Corporation Common Stock logo

Enovis Corporation Common Stock

🧾 Earnings Recap – Q2 2025

Enovis reported solid second-quarter performance, achieving 7% revenue growth and a strong shift towards improved margins under new CEO Damien McDonald’s leadership.

  • Revenue increased to $2.2 billion, up from $1.4 billion since the spin-off, supported by successful acquisitions and organic growth.
  • Adjusted EBITDA margins improved from 14% to nearly 18%, reflecting operational enhancements and disciplined capital allocation strategies.
  • Strong demand and effective cash management led to positive cash flow, amid challenges from tariffs.
  • The company is prioritizing commercial execution, innovation, and operational excellence to drive future growth and enhance patient outcomes.
  • Continued focus on embedding financial discipline across the organization to reduce costs and improve working capital efficiency.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 6, 2026
EPS-19.89
Book Value25.66
Price to Book0.98
Debt/Equity95.34
% Insiders1.468%
Growth
Revenue Growth0.05%
Estimates
Forward P/E6.21
Forward EPS4.07
Target Mean Price43.00

DCF Valuation

Tweak assumptions to recompute fair value for Enovis Corporation Common Stock (ENOV)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Enovis Corporation Common Stock Logo Enovis Corporation Common Stock Analysis (ENOV)

United States Industrials Official Website Stock

Is Enovis Corporation Common Stock a good investment? Enovis Corporation Common Stock (ENOV) is currently trading at 25.25 USD. Market analysts have a consensus price target of 43.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Enovis Corporation Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 4.07.

Investor FAQ

Does Enovis Corporation Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Enovis Corporation Common Stock?

Enovis Corporation Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -19.89.

Company Profile

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Exchange Ticker
ASE (United States) ENOV
LSE (United Kingdom) 0I1B.L

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
April 5, 2022 0.580000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion